# Alpha Teknova, Inc. (TKNO)

> Source: Nexqual · https://nexqual.com/TKNO · data as of 2026-10-29 20:00 UTC · cite as "Nexqual, Alpha Teknova, Inc. (TKNO), nexqual.com/TKNO" · informational, not investment advice.

**Price:** USD 8.09 (+2.93% on the day) · last close of Oct 29, 2026; US market closed, not a live price. Prev close 7.86 · day 7.88–8.18 · 52w 1.91–9.48 · market cap $499M · NGM

## Key facts
- Analysts: Buy (mean 2.13 on a 1–5 scale) (8 analysts), mean target USD 9.67 (range 8–12).
- Total return with dividends: 1Y +55.3% vs S&P 500 +14.8%; 5Y -64.8% vs S&P 500 +79.1%.
- Next earnings: 2026-11-04, EPS estimate USD -0.07, revenue estimate $11.8M. All companies reporting that day: https://nexqual.com/earnings/2026-11-04
- Dividend: TKNO paid no cash dividend in the last five years.
- Short interest: 14.99% of float (as of 2026-10-15), 5.4 days to cover.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/S 11.4x · EV/Sales 11.3x · P/B 8.0x · FCF yield -1.47% · Earnings yield -3.36% · Net cash $4.2M · EV $495M

## Analysts
Consensus Buy (mean 2.13 on a 1–5 scale), 8 analysts; mean target USD 9.67 (low 8, high 12).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-13 | TD Cowen | Target raised | Buy | $7 → $11 |
| 2026-09-17 | Jefferies | Initiated | Buy | $9 |
| 2026-08-11 | BTIG | Upgrade | Neutral → Buy | $8 |
| 2026-08-05 | Roth Capital | Initiated | Buy | $7 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-30) | 5Y (from 2021-10-25) |
|---|---|---|
| Total return | +55.3% | -64.8% |
| S&P 500 (SPY) | +14.8% | +79.1% |
| Per year | +55.8% | -18.8% |
| Volatility (annualized) | 80.0% | 94.9% |
| Max drawdown | -62.1% (Oct 2025→Feb 2026) | -95.5% (Nov 2021→Jul 2024) |

## Dividends
TKNO paid no cash dividend in the last five years.

## Short interest
1,649,354 shares sold short, 14.99% of the float, as of Oct 15, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 15, 2026): 1,578,870 shares (+4.5%). Days to cover: 5.4 (short shares ÷ average daily volume).

## Peers (Drug Manufacturers - Specialty & Generic)
SUPN (Supernus Pharmaceuticals, Inc.) USD 41.84 +1.85% · BHC (Bausch Health Companies Inc.) USD 8.91 +28.76% · RGC (Regencell Bioscience Holdings L) USD 6.86 -5.64% · AMLX (Amylyx Pharmaceuticals, Inc.) USD 28.68 +2.17% · LQDA (Liquidia Corporation) USD 44.99 -1.60% · INDV (Indivior Pharmaceuticals, Inc.) USD 35.25 +1.38%

## More
Full page: https://nexqual.com/TKNO · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $-0.07 | $-0.08 | +$0.01 | $11.8M | 4 |
| Next quarter (ends 2026-12-31) | $-0.08 | $-0.09 | +$0.01 | $11.1M | 4 |
| Current fiscal year (ends 2026-12-31) | $-0.29 | $-0.34 | +$0.05 | $46.0M | 4 |
| Next fiscal year (ends 2027-12-31) | $-0.19 | $-0.20 | +$0.01 | $52.7M | 1 |

## Earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | −$0.05 | −$0.07 | Beat +28.6% | — |
| — | Quarter ended Mar 31, 2026 | −$0.08 | −$0.09 | Beat +11.1% | — |
| — | Quarter ended Dec 31, 2025 | −$0.09 | −$0.09 | In line | — |
| — | Quarter ended Sep 30, 2025 | −$0.08 | −$0.09 | Beat +11.1% | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).